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ABSTRACT 
The most common treatments for rheumatoid arthritis include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease 
modifying antirheumatic drugs (DMARDs), and some biological agents. However, none of the treatments available is able to achieve the 
ultimate goal of treatment, that is, drug-free remission. However, to improve its clinically relevant parameters, nanoformulation of curcumin is 
emerging as a novel substitute for their superior therapeutic modality. It enhances its aqueous solubility and targeted delivery to the tissue of 
interest that prompts to enhance the bioavailability, better drug conveyance, and more expeditious treatment. 
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1. INTRODUCTION : 
With the passage of time, the curiosity to explore the 
medicinal benefits of natural habitat is being increased and 
has now become one of the prime areas of scientific research 
1,2 Curcuma longa (Linn.) commonly kenned as turmeric, 
belongs to Zingiberaceae family and is widely utilized as an 
ingredient spice 3,4 The history of Curcuma longa (Linn.) 
dates back over antediluvian time of Ayurveda, commonly 
found in tropical, sub-tropical and Southeast regions are 
widely cultivated areas for use as an ingredient spice. 
In previous work, we used the NF-B inhibitor Bay11-7082 to 
inhibit the maturation of DCs (6, 7). After application of NF-B 
inhibitors, DCs generated from bone marrow or peripheral 
blood precursors ex vivo expressed fewer CD40 and MHC 
class II molecules and only weakly stimulated proliferation 
and IFN- production by T cells 5,6 These DCs, when exposed 
to Ag and injected into mice, suppressed previously primed 
immune responses, including full-blown inflammatory 
arthritis, through the induction of Ag-specific regulatory CD4 
T cells (Treg cells). Experiments in knockout mice showed 
that the RelB subunit of NF-B expressed by DCs controlled 
the outcome of Ag presentation to T cells and that Ag-
specific Treg cells induced by RelBlow DCs produced IL-10 
and induced tolerance when transferred from one animal to 
another6 
Liposomes are small artificial vesicles of spherical shape that 
can be created from cholesterol and natural non-toxic 
phospholipids. Due to their size and hydrophobic and 
hydrophilic character(besides biocompatibility), liposomes 
are promising systems for drug delivery. Liposome 
properties differ considerably with lipid composition, 
surface charge, size, and the method of preparation. 
Furthermore, the choice of bilayer components determines 
the ‘rigidity’ or ‘fluidity’ and the charge of the bilayer. For 
instance, unsaturated phosphatidylcholine species from 
natural sources (egg or soybean phosphatidylcholine) give 
much more permeable and less stable bilayers, whereas the 
saturated phospholipids with long acyl chains (for example, 
dipalmitoylphos phatidylcholine) form a rigid, rather 
impermeable bilayer structure. 
2. MECHANISM OF LIPOSOME FORMATION:  
The basic part of liposome is formed by phospholipids, 
which are amphiphilic molecules (having a hydrophilic head 
and hydrophobic tail). The hydrophilic part is mainly 
phosphoric acid bound to a water soluble molecule, whereas, 
the hydrophobic part consists of two fatty acid chains with 
10 – 24 carbon atoms and 0 – 6 double bonds in each chain8. 
3. COMPONENTS OF LIPOSOME STRUCTURE: 
Liposomes are versatile in that the entire membrane of the 
liposome can be composed of either natural or man-made 
phospholipids. The properties of the liposomes can be 
changed entirely depending on the phospholipids used. The 
basic components of liposomes are phospholipids which are 
stabilised by cholesterol, with other stabilisers sometimes 
added to the mixture depending on the specific use of the 
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liposome. Many different types of lipids and lipid mixtures 
can be used or mixed-and-matched to obtain a certain type 
of liposome.9 
4. LIPOSOMES PREPARATION PROCEDURES 
4.1 Classical Technique: 
There are four classical methods of liposome manufacture. 
The difference between the various methods is the way in 
which lipids are drying down from organic solvents and then 
redispersed in aqueous media.10 These steps are performed 
individually or are mostly combined. 
a. Hydration of a Thin Lipid Film:  
This is the original method which was initially used for 
liposomes production.11 A mixture of phospholipid and 
cholesterol were dispersed in organic solvent. Then, the 
organic solvent was removed by means of evaporation 
(using a Rotary Evaporator at reduced pressure). 
b. Detergent Dialysis: 
A pilot plant under the trade name of LIPOPREPR II-CIS is 
available from Diachema, AG, Switzerland. The production 
capacity at higher lipid concentration (80 mg/ml) is 30 ml 
liposomes/minute. But when lipid concentration is 10-20 
mg/ml then up to many liters of liposomes can be produced. 
In USA, LIPOPREPR is marketed by Dianorm-Geraete.12  
c. Microfluidization: 
A method based on microfuidization/ 
microemulsification/homogenization was developed for the 
preparation of liposomes. MICROFLUIDIZERR is available 
from Microfudics Corporation, Massachusetts, USA. A plot 
plant based on this technology can product about 20 
gallon/minute of liposomes in 50-200 nm size range. The 
encapsulation efficiency of up to 75% could be obtained.13 
Aqueous dispersions of liposomes often have tendency to 
aggregate or fuse and may he susceptible to hydrolysis and 
or oxidation.  
d. Proliposomes: 
 In proliposomes, lipid and drug are coated onto a soluble 
carrier to form free-flowing granular material which on 
hydration forms an isotonic liposomal suspension. The 
proliposome approach may provide an opportunity for cost-
effective large scale manufacturing of liposomes containing 
particularly lipophilic drugs.16  
e. Lyophilization: 
 Freeze-drying (lyophilization) involves the removal of 
water from products in the frozen state at extremely low 
pressures. The process is generally used to dry products that 
are thermolabile and would be destroyed by heat-drying. 
The technique has a great potential as a method to solve long 
term stability problems with respect to liposomal stability. It 
is exposed that leakage of entrapped materials may take 
place during the process of freeze- drying and on 
reconstitution.16 
5. DESIGNING LIPOSOMES TO ACHIEVE 
OPTIMIZED PROPERTIES: 
Drug loading and control of the drug release rate It soon 
became clear that there were a number of problems 
associated with the in vivo use of the 1st generation 
liposomes, sometimes termed ‘classical’ or conventional 
liposomes. A very early observation was the difficulty in 
retaining some types of entrapped molecules in the liposome 
interior17 Drug release was shown to be affected by 
exposure to serum proteins18 Changing the content of the 
liposome bilayer, in particular by incorporation of 
cholesterol was shown to ‘tighten’ fluid bilayers and reduce 
the leakage of contents from liposomes. Switching 19 from a 
fluid phase phospholipid bilayer to a solid phase bilayer also 
reduced leakage as did incorporation of sphingomyelin into 
liposomes. 
6. CONCLUSIONS: 
 Liposomes have been explored for various diseases ranging 
from cancer treatment to pain management. Advantages of 
using liposomal formulations include: (1) the properties of 
these liposomes like pharmacokinetics and 
pharmacodynamics are easily maneuverable, (2) improved 
bioavailability and (3) reduced toxicity. Different liposomal 
formulations are made for various applications such as 
temperature sensitive liposomes, cationic liposomes and 
liposomal vaccines. Collectively, these liposomal 
formulations have the ability to enhance or to overcome the 
limitations of conventional therapies. Furthermore, 
liposomes have shown great promise in their design to label 
them with molecular probes for imaging. Exploitation of 
liposomal characteristics to improve the target specificity 
and encapsulation can achieve significant therapeutic 
efficacy. Many liposomal formulations have successfully 
translated to clinical applications after extensive research on 
their efficacy and preclinical trials have demonstrated a 
greater impact on patients with various ailments, thereby 
improving the quality of life. 
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